Kyocera has developed a new ultra-thin meta-lens that can shift focal positions depending on the wavelength of light.

Addex spin-out Neurosterix begins phase 1 study with M4 PAM - NTX-253 for schizophrenia: Geneva, Switzerland Thursday, January 8, 2026, 12:00 Hrs [IST] Addex Therapeutics, a clini ...

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added ...

Positive interim efficacy data in 2025 underscore potential of ETX101 as a one-time, disease-modifying medicine for Dravet syndrome –– Internal GMP manufacturing capable of supporting pivotal trial ...

Epicrispr, a clinical-stage company pioneering gene-modulating therapies, today reported early clinical data from its ongoing ...

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...

Erich Rajkovic Erich Rajkovic - new Eleva CBO Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in ...

Even though it will likely be another year until the adoption of Wi-Fi 8, also known as IEEE 802.11bn, first router ...

Cereno Scientific (Nasdaq First North: CRNO B) ("the Company"), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, annou ...

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan's 44th ...

Addressing the core issues of latency and integration in developing audio amplifiers for today’s smart cockpits.